Favorable safety profile of moderate hypofractionated over normofractionated radiotherapy in breast cancer patients: a multicentric prospective real-life data farming analysis.

Date publication

avril 2022

Journal

Radiation oncology (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CLAVIER Jean-Baptiste , Dr GUIHARD Sébastien

Tous les auteurs :
Issoufaly I, Petit C, Guihard S, Eugène R, Jung L, Clavier JB, Servagi Vernat S, Bellefqih S, Verret B, Bonnet N, Deutsch É, Rivera S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35443729

Résumé

Moderately hypofractionated whole-breast radiotherapy (HFRT) has proven to be as safe and efficient as normofractionated radiotherapy (NFRT) in randomized trials resulting in major changes in clinical practice. Toxicity rates observed in selected clinical trial patients may differ from those observed in unselected patients with possible comorbidities and frailty in real-life. This study aimed to examine the influence of HFRT versus NFRT on acute toxicity and identify risks factors of dermatitis in real-life patients.

Mots clés

Acute toxicity, Breast cancer, Data-farming, Hypofractionation, Radiotherapy, Real-life data

Référence

Radiat Oncol. 2022 Apr 20;17(1):80